Last reviewed · How we verify
Placebo to alogliptin
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo to alogliptin |
|---|---|
| Sponsor | Takeda |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Alogliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner, resulting in improved glycemic control without causing hypoglycemia.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin (PHASE3)
- Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy (PHASE3)
- A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322 (PHASE4)
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (PHASE3)
- Phase 3 Alogliptin Pediatric Study (PHASE3)
- The Practical Evidence of Antidiabetic Combination Therapy in Korea (PHASE4)
- Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes (PHASE1)
- Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to alogliptin CI brief — competitive landscape report
- Placebo to alogliptin updates RSS · CI watch RSS
- Takeda portfolio CI